METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER USING BIFUNCTIONAL SRC 3 shRNA
The present invention includes compositions and methods treating triple negative breast cancer comprising administering a therapeutically effective amount of a formulation that includes vector that expresses an SRC-1-specific bifunctional shRNA, an SRC-3-specific bifunctional shRNA, or both, to impair triple negative breast cancer cell growth.
1 . A method for treating triple negative breast cancer comprising administering a therapeutically effective amount of a formulation that includes vector that expresses an SRC-1-specific bifunctional shRNA, an SRC-3-specific bifunctional shRNA, or both, to impair triple negative breast cancer cell growth.
2 . The method of claim 1 , wherein the formulation further comprises a cationic liposomal preparation.
3 . The method of claim 2 , wherein the cationic liposomal preparation comprises a single vector that encodes the SRC-1-specific bifunctional shRNA, the SRC-3-specific bifunctional shRNA, or both the SRC-1-specific bifunctional shRNA and the SRC-3-specific bifunctional shRNA.
4 . The method of claim 1 , wherein the one or more shRNA's is comprises a sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ. ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, or combinations or modifications thereof.
5 . The method of claim 1 , wherein a sequence arrangement for the shRNA comprises a 5′ stem arm-19 nucleotide target (SRC-3 gene)-TA-15 nucleotide loop-19 nucleotide target complementary sequence-3′ stem arm-Spacer-5′ stem arm-19 nucleotide target variant-TA-15 nucleotide loop-19 nucleotide target complementary sequence-3′ stem arm.
6 . The method of claim 1 , wherein the one or more polycations is a 10 kDA polyethylene glycol (PEG)-substituted cysteine-lysine 3-mer peptide (CK30PEG10k).
7 . The method of claim 1 , wherein the compacted DNA nanoparticles are further encapsulated in a liposome.
8 . The method of claim 1 , wherein the liposome is a bilamellar invaginated vesicle (BIV).
9 . The method of claim 1 , wherein the triple negative breast cancer is resistant to chemotherapeutic agents.
10 . A method of treating a triple negative breast cancer in a human subject comprising the steps of:
identifying a human subject in need for suppression of triple negative breast cancer cell growth; and
administering an expression vector in a therapeutic agent carrier complex to the human subject in an amount sufficient to suppress the growth of a triple negative breast cancer cells;
wherein the expression vector expresses one or more bifunctional short hairpin RNA (shRNA) capable inhibiting an expression of an SRC-1 gene, an SRC-3 gene, or both, wherein the one or more shRNA comprise a bifunctional RNA molecule that activates concurrently both a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of the SRC-1 gene, the SRC-3 gene, or both.
11 . The method of claim 10 , wherein the one or more shRNAs are selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ. ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and combinations or modifications thereof.
12 . The method of claim 10 , wherein a sequence arrangement for the shRNA comprises a 5′ stem arm-19 nucleotide target (SRC-3 gene)-TA-15 nucleotide loop-19 nucleotide target complementary sequence-3′ stem arm-Spacer-5′ stem arm-19 nucleotide target variant-TA-15 nucleotide loop-19 nucleotide target complementary sequence-3′ stem arm.
13 . The method of claim 10 , wherein the therapeutic agent carrier is a compacted DNA nanoparticle or a reversibly masked liposome decorated with one or more receptor targeting moieties, wherein the one or more receptor targeting moieties are small molecule bivalent beta-turn mimics.
14 . The method of claim 10 , wherein the therapeutic agent carrier is a compacted DNA nanoparticle that is compacted with one or more polycations, wherein the one or more polycations comprises a 10 kDA polyethylene glycol (PEG)-substituted cysteine-lysine 3-mer peptide (CK 30 PEG10k) or a 30-mer lysine condensing peptide.
15 . The method of claim 10 , wherein the reversibly masked liposome is a bilamellar invaginated vesicle (BIV).
16 . The method of claim 10 , wherein the compacted DNA nanoparticles are further encapsulated in a liposome.
17 . The method of claim 10 , wherein the tumor cell or breast cancer is resistant to tamoxifen therapy.
18 . The method of claim 10 , further comprising administering tamoxifen.
19 . The method of claim 10 , further comprising the step of administering the vector before, after, or concurrently as a combination therapy with one or more treatment methods selected from the group consisting of chemotherapy, radiation therapy, surgical intervention, antibody therapy, Vitamin D therapy, or any combinations thereof.
20 . The method of claim 10 , wherein the triple negative breast cancer is resistant to chemotherapeutic agents.
21 . A method of treating one or more cancers resistant to chemotherapy, increasing effectiveness of one or more chemotherapeutic agents, or both in a subject comprising the steps of:
identifying the human or animal subject having the cancer resistant to the chemotherapeutic agents or in need of increased effectiveness of the one or more chemotherapeutic agents, wherein the breast cancer is a triple negative breast cancer; and
administering an expression vector in a therapeutic agent carrier complex to the human or animal subject in an amount sufficient to suppress or inhibit an expression of an SRC-1 gene, an SRC-3 gene, or both in the subject, wherein the expression vector expresses one or more bifunctional short hairpin RNA (shRNA) capable inhibiting the expression of the SRC-1 gene, the SRC-3 gene, or both in one or more triple negative breast cancer cells in the subject via RNA interference, wherein the inhibition results in an enhanced action of the one or more chemotherapeutic agents leading to an apoptosis, an arrested proliferation, or a reduced invasiveness of one or more triple negative breast cancer cells;
wherein the one or more bifunctional shRNA activate a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of SRC-1, SRC-3, or both.
22 . The method of claim 21 , wherein the one or more chemotherapeutic agents comprise platinum drugs, carboplatin, tamoxifen, ER antagonists, or any combinations thereof.
23 . The method of claim 21 , wherein the cancers are selected from the group consisting of colon, breast, pancreatic, prostate, or any combinations thereof.
24 . The method of claim 21 , wherein the one or more shRNAs are selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ. ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and combinations or modifications thereof.
25 . The method of claim 21 , wherein the vector is administered before, after, or concurrently as with the one or more chemotherapeutic agents.
26 . The method of claim 21 , wherein the triple negative breast cancer is resistant to chemotherapeutic agents.